Evidence-Based Complementary and Alternative Medicine-20 Mar 2019 大黄素

郑重说明:

我司所有产品仅供科研实验，不得用于注射、食用或其他用途

产品关键词：丹酚酸B 金丝桃苷人参皂苷rb1 雷公藤甲素

guanyuwomen关于德思特

联系方式

服务热线：

028-8500-3950

公司传真：	028-85589956
公司邮箱：	sales@tcmlmt.com
公司网址：	www.028desite.com
公司地址：	四川省成都市温江区海科路西段128号5栋

发表文献展示

当前位置:首页关于德思特 > 发表文献展示 >

时间：2020-09-03 浏览次数：分享到：

Pharmacokinetic and Bioavailability Studies of Embelin after Intravenous and Oral Administration to Rats
期刊名：Evidence-Based Complementary and Alternative Medicine
文献编号：DOI 10.1155/2019/9682495
文献地址：https://www.hindawi.com/journals/ecam/2019/9682495/
发表日期：20 Mar 2019

Abstract
Embelin exhibits the broad bioactivities such as antitumor, antifertility, antidiabetic, anti-inflammatory, antioxidant, anticonvulsant, anxiolytic, antimicrobial, and hepatoprotective activity. In order to further understand the pharmacokinetic characteristics and oral bioavailability of embelin in vivo, the concentration of embelin in rat plasma was determined by a sensitive high-performance liquid chromatography with diode array detector (HPLC-DAD). The preparation of samples was accomplished by a simple precipitating protein with methanol. Emodin was selected as the internal standard (IS). Embelin and IS were completely separated on an analytical column (Extend-C18, 4.6 × 250 mm, 5 μm) using 0.1% phosphoric acid in methanol and 0.1% phosphoric acid in aqueous solution (90:10, v/v) as the mobile phase. The lower limit of quantification was 0.15 μg/mL. Oral bioavailability of embelin was 30.2 ± 11.9%. This study could provide the information about pharmacokinetics and oral bioavailability of embelin, which was useful to assess the clinic efficacy and safety and promote further development of embelin.

Emodin was purchased from Chengdu Desite Biological Technology Co., Ltd. (Chengdu, China)

上一篇：Frontiers in pharmacology-09 January 2019 异槲皮苷穗花杉双黄

下一篇：Journal of Separation Science-03 February 2018 绿原酸芍药苷

Afrormosine CAS:550-79-8 中药对照品标准品

产品编码：DA0040产品名称：Afrormosine英文名:AfrormosineCAS登录...